ETONHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. hold a median 12-month price target of $70 — +27.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Eton Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ETON, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +27.8% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | B. Riley Securities | Reiterates | Buy | $40 → $70 |
| 14 Aug 2026 | Canaccord Genuity | Maintains | Buy | $60 → $68 |
| 14 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $65 → $70 |
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $57 → $65 |
| 28 July 2026 | Craig-Hallum | Maintains | Buy | $40 → $62 |
| 28 July 2026 | Craig-Hallum | Maintains | Buy | — |
| 17 July 2026 | Canaccord Genuity | Initiates | Buy | $60 |
| 17 July 2026 | Canaccord Genuity | Initiates | Buy | — |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | $52 → $57 |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 20 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 20 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 May 2025 | B. Riley Securities | Reiterates | Buy | — |
| 14 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 19 Mar 2025 | B. Riley Securities | Reiterates | Buy | — |
| 19 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ETON appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Eton Pharmaceuticals, Inc. returned +164.2% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 11% of US stocks
Cheaper than 3% of US stocks
Cheaper than 4% of US stocks
Higher than 92% of US stocks
Higher than 83% of US stocks
Higher than 81% of US stocks
Higher than 90% of US stocks
Higher than 74% of US stocks
Higher than 90% of US stocks
Higher than 95% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Eton Pharmaceuticals, Inc. has a market value of $1.6B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $105.6M. The latest quarter grew 98.6% year on year.
Net income over the same four quarters: $12.7M, a 12.0% net margin.
Diluted earnings per share, trailing twelve months: $0.38.
Free cash flow in the twelve months to 30 June 2026: −$268K.
Trailing P/E: 139.0×; forward P/E: 21.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Eton Pharmaceuticals, Inc. employs 44 people — $2.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Eton Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Eton Pharmaceuticals announced the U.S. commercial availability of IMPAVIDO (miltefosine) capsules, marking the launch of this rare disease treatment. The announcement was made by the Company on September 28, 2026.
Why it matters — This commercial launch brings a new product to market, potentially expanding Eton's commercial portfolio in the rare disease space.
Eton Pharmaceuticals announced that members of its executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference, which will be held September 8-10, 2026 in Boston, MA.
Why it matters — A ETON watcher would care because the company's leadership is engaging with investors and industry participants at a major healthcare conference, offering an opportunity for direct dialogue about the company.
A news item highlights three biotech stocks, each of which rose after recent earnings reports and has outperformed 97% of stocks over the past 12 months, with Eton Pharmaceuticals included among them based on its strong chart performance.
Why it matters — For Eton Pharmaceuticals watchers, the item signals that ETON is being recognized among top-performing biotech stocks with notable relative strength.
Eton Pharmaceuticals reported quarterly results that exceeded expectations on both revenue and earnings. Management also announced it is licensing a new drug and raised its financial guidance through the end of 2026.
Why it matters — A beat on earnings, a new licensing deal, and higher forward guidance collectively signal strengthening business momentum for the company.
Eton Pharmaceuticals reported record Q2 2026 results, with product sales doubling year-over-year, and raised its full-year revenue guidance to over $145 million. The company outlined plans to exceed $500 million in peak annual sales through organic growth, pipeline development, and acquisitions in rare disease markets.
Why it matters — A shareholder would care because the company is projecting significant margin expansion, with adjusted EBITDA margins expected to exceed 35% in 2026 and gross margins rising above 75%.
The 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. have a median 12-month price target of $70, with estimates ranging from $68 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Eton Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Eton Pharmaceuticals, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +27.8% from the last close, and Ticker Nerd's factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Eton Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ETON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $68 to $76 over the next 12 months.
Eton Pharmaceuticals, Inc. returned +164.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases.
The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules". Eton Pharmaceuticals announced the U.S. commercial availability of IMPAVIDO (miltefosine) capsules, marking the launch of this rare disease treatment. The announcement was made by the Company on September 28, 2026.
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases. Eton Pharmaceuticals, Inc. offers a commercial portfolio that includes therapies for adrenal insufficiency, severe primary IGF-1 deficiency, Wilson disease, phenylketonuria, homocystinuria, tyrosinemia type 1, and central diabetes insipidus, along with prescription products such as oral suspensions, injectable formulations, and oral solutions. The company also works across pediatric and adult care settings, supporting medications used in endocrine, metabolic, and other niche therapeutic areas. Based in Deer Park, Illinois, Eton Pharmaceuticals, Inc. plays a focused role in the rare-disease market by bringing specialized medicines to patients and healthcare providers through a mix of in-licensed products, commercial launches, and targeted product development.
CEO Mr. Sean E. Brynjelsen · 44 employees · United States · https://www.etonpharma.com
